Skye Bioscience, Inc.
Skye Bioscience, Inc.
Your view on SKYE
Overview
What the company does, where it operates, and who runs it.
About Skye Bioscience, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Punit S. Dhillon
- Headquarters
- 11250 El Camino Real, San Diego, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Punit S. Dhillon
- Headquarters
- 11250 El Camino Real, San Diego, CA, US
Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension.
It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy.
The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Skye Bioscience, Inc., and the rating behind it. SKYE last traded at $2.04; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Skye Bioscience, Inc.. Starting points for Skye Bioscience, Inc.: EPS -$10.18, beta 2.90 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Skye Bioscience, Inc.. Skye Bioscience, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Skye Bioscience, Inc.. Trailing twelve-month EPS for Skye Bioscience, Inc. stands at -$10.18. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Skye Bioscience, Inc.. Skye Bioscience, Inc. has reported as a listed company since 2014. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Skye Bioscience, Inc. valued side by side against its closest peers. Skye Bioscience, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Skye Bioscience, Inc., and how their positions are changing. At a $9.0M market value, institutional positions materially move Skye Bioscience, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Skye Bioscience, Inc. executives and directors. Shares of Skye Bioscience, Inc. have traded between $1.14 and $5.75 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Skye Bioscience, Inc.. Skye Bioscience, Inc. is a $9.0M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Skye Bioscience, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Skye Bioscience, Inc.. Coverage tracks Skye Bioscience, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.